M. Baccarani Et Al. , "A prospective study of imatinib 400 mg vs 800 mg frontline in high risk Ph plus chronic myeloid leukemia (CML) patients," 49th Annual Meeting of the American-Society-of-Hematology , vol.110, Georgia, United States Of America, 2007
Baccarani, M. Et Al. 2007. A prospective study of imatinib 400 mg vs 800 mg frontline in high risk Ph plus chronic myeloid leukemia (CML) patients. 49th Annual Meeting of the American-Society-of-Hematology , (Georgia, United States Of America).
Baccarani, M., Castagnetti, F., Porkka, K., Nielsen, J. L., Hjorth-Hansen, H., Haznedaroglu, I., ... Nagler, A.(2007). A prospective study of imatinib 400 mg vs 800 mg frontline in high risk Ph plus chronic myeloid leukemia (CML) patients . 49th Annual Meeting of the American-Society-of-Hematology, Georgia, United States Of America
Baccarani, Michele Et Al. "A prospective study of imatinib 400 mg vs 800 mg frontline in high risk Ph plus chronic myeloid leukemia (CML) patients," 49th Annual Meeting of the American-Society-of-Hematology, Georgia, United States Of America, 2007
Baccarani, Michele Et Al. "A prospective study of imatinib 400 mg vs 800 mg frontline in high risk Ph plus chronic myeloid leukemia (CML) patients." 49th Annual Meeting of the American-Society-of-Hematology , Georgia, United States Of America, 2007
Baccarani, M. Et Al. (2007) . "A prospective study of imatinib 400 mg vs 800 mg frontline in high risk Ph plus chronic myeloid leukemia (CML) patients." 49th Annual Meeting of the American-Society-of-Hematology , Georgia, United States Of America.
@conferencepaper{conferencepaper, author={Michele Baccarani Et Al. }, title={A prospective study of imatinib 400 mg vs 800 mg frontline in high risk Ph plus chronic myeloid leukemia (CML) patients}, congress name={49th Annual Meeting of the American-Society-of-Hematology}, city={Georgia}, country={United States Of America}, year={2007}}